Clinical Trial Detail

NCT ID NCT04311710
Title A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

hepatocellular carcinoma

transitional cell carcinoma

lung non-small cell carcinoma

renal cell carcinoma

melanoma

Therapies

Ipilimumab + Nivolumab

Ipilimumab + Nivolumab + rHuPH20

Age Groups: senior adult

Additional content available in CKB BOOST